AnaptysBio Looking for More Funding in IPO
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 232
Merrill Lynch Has 4 Large Cap Pharmaceutical Dividend Stocks for 2016
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and growth next year.
Could These Hot 2015 Biotech IPOs Be 2016 Buyout Targets?
While there is certainly no guarantee that any of these hot biotech companies is bought, they each offer aggressive accounts big potential upside and have unique products and clinical possibilities going forward.
Major Pharma Short Interest Takes Another Giant Leap Forward
The short interest data have been released for the December 15 settlement date, and for most of the selected pharmaceutical stocks short interest was up.
Short Interest Remains Mixed in Major Biotechs
The short interest data are out for the December 15 settlement date, and short interest continued to be mixed in these selected biotech stocks.
4 Ignored Biotech Stocks for 2016
Biotech gets a lot of sustained attention, but some stocks still fall through the cracks, either due to recent failures or general lack of interest.
Why Breakthrough FDA Approval of Gout Treatment May Matter So Much
Good news for those who suffer from high levels of uric acid and from gout: the FDA has approved a new gout treatment.
pSivida Soars on Positive Late Stage Results
pSivida was leading the bulls in Tuesday’s session on positive results from a late stage trial of Medidur.
How AVEO Is Winning on Its Newest Licensing Agreement
AVEO Pharmaceuticals was leading the bulls in Monday’s session on news of an exclusive licensing agreement.
Collegium Pharma Announces Secondary Offering
Collegium Pharmaceutical has filed with the U.S. Securities and Exchange Commission (SEC) regarding a secondary offering.
KemPharm Prepares for Secondary Offering
KemPharm expects to price its 3 million shares around last Thursday's closing price of $18.88, which would value the entire secondary offering at up to more than $65 million.
Intercept Pharma Disappoints on FDA Extension
Intercept Pharmaceuticals announced that the FDA has extended the PDUFA date for its Priority Review of obeticholic acid in primary biliary cholangitis.
4 Top Biotech Stocks for 2016
Biotech looks set to close out 2015 as its worst performing year since 2008. But can we expect a better 2016 for this exciting sector?
Martin Shkreli Stocks Turn Toxic Upon Arrest
As quickly as KaloBios Pharmaceuticals shares shot up, they are dropping after its newly named chief executive, Martin Shkreli, was arrested.
Top Cowen Health Care and Biotech Best Idea Stock Picks for 2016
All these Cowen picks offer compelling values for 2016, and all have backed up enough in price for investors to get an outstanding entry point.